Obesity is a predictor in prostate cancer patients receiving prostatectomy after neoadjuvant hormonal therapy. Issue 2 (April 2020)

• Record Type: Journal Article
• Authors: Sun, Lijiang; Xu, Ting; Yuan, Xiaoliang; Liu, Feng; Guan, Fengju; Ye, Dingwei; Zhang, Guiming
• Is Part Of: Tumori. Volume 106:Issue 2(2020)
• Page Start: 133
• Page End: 138
• Publication Date: 2020-04
• Subjects: Prostatic neoplasms -- overweight -- neoadjuvant hormonal therapy -- pathology; Cancer -- Periodicals; 616.994
• DOI: 10.1177/0300891619868281
• Languages: English
• ISSNs: 0300-8916

Abstract

Objective: This study aimed to investigate the relationship between obesity and pathologic features and biochemical recurrence in patients with prostate cancer (PCa) undergoing radical prostatectomy (RP) after neoadjuvant hormonal therapy (NHT). Methods: A total of 422 consecutive patients with clinically localized PCa who received NHT before RP were retrospectively analyzed. Unconditional multiple logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) regarding probability. A receiver operating characteristic (ROC) curve was used to assess the efficacy of the predictive variables. Castration resistance free survival curves were obtained using the Kaplan-Meier method, and were compared using the log-rank test. Results: Being overweight was associated with an increased risk of positive margins (OR 2.281; 95% CI 1.292–4.028) after adjusting for potential confounders. The area under the ROC curve for overweight patients was larger than that for patients in the normal weight range. There was no significant difference between the overweight and normal weight groups regarding castration resistance free survival. Conclusions: Being overweight was associated with positive margins in patients with PCa undergoing RP after NHT.